Abstract: The multiple functions of glutamate include regulation of neural development and stem cells. While the importance of the ionotropic glutamate receptors is well-established, less is known about the role of metabotropic glutamate receptors (mGluRs). In this study, we examined the effects of pharmacological activation and inhibition of mGluR2/3 on proliferation, differentiation and viability of a human neural stem cell line. Immunofluorescence staining revealed the presence of mGluR2/3 receptors on both proliferating and differentiating stem cells, including cells differentiated into b-tubulin III-positive immature neurons and glial fibrillary acidic protein-positive astrocytes. Stimulation of mGluR2/3 receptors during cell propagation using the agonist (2S,2 0 R,3 0 R)-2-(2 0 ,3 0 -dicarboxycyclopropyl) glycine (DCG-IV) increased total cell numbers significantly (60% compared to untreated controls). This effect could be inhibited by the specific antagonist (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495). The antagonist alone had no effect. No significant decrease in cell death was found following mGluR2/3 stimulation, suggesting that the observed elevation in cell number was not related to cell viability. Subsequent differentiation of the cells resulted in a slight decrease in b-tubulin III-positive neurons (5.2-3.2% of total cells) for DCG-IV pre-treated cultures. Treatment with DCG-IV and LY342495 during cell differentiation alone had no such effect. Western blot analysis revealed that the active, dimeric form of mGluR2/3 was mainly present on the proliferating cells, which may explain our findings. This study emphasizes the importance of glutamate and mGluRs on regulation of human neural stem cells and suggests a significant role of mGluR2/3 during cell proliferation.
Glutamate is the major excitatory transmitter in the central nervous system [1, 2] exerting its effect by acting on ionotropic (iGluRs) and metabotropic glutamate receptors (mGluRs) [3] . MGluRs are divided into three groups based on sequence homology, agonist pharmacology and signal transduction pathways. Group I receptors (mGluR1,5) are positively coupled to phospholipase C, whereas group II (mGluR2,3) and group III (mGluR4, 6, 7, 8) receptors are negatively coupled to the adenylate cyclase [4] [5] [6] .
Several studies suggest that mGluRs play a significant role in the regulation of neural development. MGluRs are expressed on neuronal precursor cells during embryonic development in both rodents and human beings [7] [8] [9] [10] . Activation of mGluR3 and mGluR5 promotes proliferation and survival of neural stem cells (NSCs) derived from mouse embryonic forebrain [11] . NSCs derived from the developing human forebrain express group I mGluRs and respond to low-dose glutamate treatment with increased proliferation and decreased cell death [12] . In addition, mGluRs appear to affect postnatal neurogenesis. In the adult murine brain, mGluRs can be found in the neurogenic zones [13] [14] [15] , and in vitro studies of NSCs derived from these zones have revealed that receptor manipulation influence proliferation, survival and differentiation of NSCs [11, 13, 14, 16] .
The group II mGluRs are mainly present on presynaptic membranes on both glutamatergic and GABAergic neurons as well as on glial cells [17] . Varying results have been reported regarding the expression of group II mGluRs during development. In one study, neural precursors from mice have been shown to express mGluR2 mRNA [18] , whereas in other studies it could not be detected [11, 14] . More is known about mGluR3, which is expressed by NSCs in the developing and adult rodent forebrain, where it promotes survival and proliferation [11, 13, 16] . However, little is known about the presence and functional importance of group II mGluRs on human NSCs. In one study, adult human glial precursor cells were shown to express mGluR3 and mGluR5a [19] .
In this study, we investigated the expression of group II metabotropic glutamate receptors (mGluR2/3) on human forebrainderived NSCs and whether pharmacological activation of these receptors would influence cell proliferation and differentiation.
Materials and Methods
Human neural stem cells (hNS1 cells). Procedures for collection of foetal tissue, cell isolation and immortalization are described elsewhere [20] . Briefly, human foetal tissue (striatum and adjacent subventricular zone; gestational week 10-10.5, crown-rump length 30 mm) was donated for research after written informed consent of the women seeking abortion. Tissue procurement was performed in accordance with the Declaration of Helsinki and in agreement with the ethical guidelines of the Network of European CNS Transplantation and Restoration (NECTAR). Approval to use these tissues for research was granted by the Lund University Hospital Ethical Committee, and their use was in compliance with Spanish law 35/1988 on Assisted Reproduction.
Immortalization of cells was carried out by infection with a retroviral vector (LTR-vmyc-SV40p-Neo-LTR; replication defective) coding for v-myc, a p100 gag-myc fusion protein isolated from the avian virus genome [20] . The resulting hNS1 cells divide approximately every 40 hr and have proven to be stable after long-term culture [21] . Neurons derived from hNS1 are electrophysiologically active, and following transplantation, hNS1 cells engraft and differentiate in the rat brain without tumour formation [20, 22] .
Propagation and differentiation of hNS1 cells. hNS1 cells were grown as monolayers in poly-L-lysine (PLL, 10 lg/ml; Sigma, Brøndby, Denmark)-coated culture flasks (NUNC T25) in HNSC.100 medium consisting of DMEM/F12 (Gibco, Taastrup, Denmark), 6 g/l glucose (Sigma), 5 mM HEPES (Gibco), 0.5% (v/v) AlbuMAX-1 (Gibco), 1% (v/v) NEAA (Sigma) and 1% (v/) N2 supplement (Gibco) supplemented with 20 ng/ml human recombinant epidermal growth factor (EGF; R&D Systems, Abingdon, UK) and 20 ng/ml human recombinant basic fibroblast growth factor (bFGF; R&D Systems). The medium was replaced every 3 days. Cells were passaged when confluent. In brief, the medium was removed and adherent hNS1 cells were washed with Hank's balanced salt solution without calcium, magnesium or phenol red (HBSS, Gibco). Cells were then trypsinized (trypsin-EDTA in HBSS; Gibco) for 2-3 min. in an incubator at 37°C. The trypsin activity was blocked by serum-containing medium, and the hNS1 cells were suspended and centrifuged at 130 9 g for 5 min. at 4°C. After centrifugation, the supernatant was removed, and the cells resuspended and seeded into new PLL-coated culture flasks.
To investigate the role of mGluR2/3 on proliferation of the hNS1 cells, the group II mGluR agonist (2S,2 0 R,3 0 R)-2-(2 0 ,3 0 -dicarboxycyclopropyl) glycine (DCG-IV; 1 lM, Tocris) and/or the group II mGluR antagonist (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495; 1 lm, Tocris) were added to the HNSC.100 medium in combination with EGF and bFGF. The solvent of the drugs, either sterile water or DMSO, was added to control medium in identical amounts; 35,000 cells/well were seeded in 6-well Costar plates (Sigma) and allowed to proliferate for 4 days.
The role of mGluR2/3 on the differentiation of the hNS1 cells was investigated by adding DCG-IV (1 lM) to HNSC.100 medium without EGF and bFGF. The solvent of the drug, DMSO, was added to control medium; 70,000 cells/well were seeded in 6-well Costar plates and allowed to spontaneously differentiate for 10 days without EGF and bFGF. The medium as changed twice a week.
To investigate the differentiation potential of hNS1 cells after activation of mGluR2/3 during proliferation (DCG-IV (1 lm) for 4 days), 70,000 cells/well were seeded in 6-well Costar plates and allowed to differentiate for 10 days in medium without EGF, bFGF and DCG-IV. Double immunofluorescence was performed as follows: cultures were washed in 0.05 M TBS (pH 7.4) containing 1% Triton X-100 for 3 9 15 min. and incubated with 5% goat serum (Gibco) in TBS for 30 min. The cultures were then incubated for 48 hr at 4°C with the following antibodies: monoclonal mouse anti-HN (Chemicon) 1:2000, anti-GFAP CY3 (Sigma) 1:800, monoclonal mouse anti-b-tubulin III (Sigma) 1:1000 or polyclonal rabbit anti-mGluR2/3 (Sigma) 1:1000 in TBS with 5% goat serum. After rinsing in TBS with 1% Triton X-100 for 3 9 15 min., cultures were incubated for 2 hr with antimouse CY3 (Jackson, Skanderborg, Denmark) 1:200 or anti-rabbit-CY5 (Jackson) 1:200 in 5% goat serum. The cultures were then washed in TBS with 1% Triton X-100 for 3 9 15 min. and water for 2 9 15 min.
Hoechst staining. Hoechst staining of cell nuclei was performed (proliferating, DCG-IV-treated cells versus untreated controls) to investigate the effect of DCG-IV on cell proliferation and nuclear morphology/cell death [23] . Fixed cells were washed in 0.05 M TBS (pH 7.4) containing 1% Triton X-100 for 3 9 15 min., 2 lg/ml Hoechst 33342 (Sigma) in TBS was added for 2 min. followed by wash in TBS with 1% Triton X-100 for 3 9 15 min. and water for 2 9 15 min.
Cell counting. Quantification of HN-, GFAP-and b-tubulin II-positive cells was performed using a bright-field microscope with an ocular counting grid (Olympus, Ballerup, Denmark; counting area 1 mm 2 ) at 9100 magnification. Analyses were based on six randomly selected areas per well, chosen by pre-defined fix points in a grid placed underneath the culture trays. Only cells displaying an intense immunostaining, wellpreserved cellular structure and a distinct nucleus were counted. All cell counts were performed by experimenter blind to sample identity.
Western blotting. Cell pellets were lysed in PBS (Life Technologies) with 1% Triton X-100 and protease inhibitor (Complete Mini Tablets, Roche, Copenhagen, Denmark) and sonicated for 2 9 10 sec. at 10 amplitude microns on ice. Protein concentrations were determined with BCA Protein Assay Kit (Thermo Scientific, Slangerup, Denmark), and equal amounts of protein from each sample were diluted 1:1 in NuPAGE LDS sample Buffer (29) (Invitrogen, Taastrup, Denmark). Proteins were separated on NuPAGE Bis-Tris Gels 4-12% (Invitrogen) at 200 V with NuPAGE MOPS SDS running buffer (Invitrogen) and transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen) using the iBlot â Dry Blotting System (Invitrogen) using the Trans-Blot Turbo Transfer System (Bio-Rad, Copenhagen, Denmark). SeeBlue Plus2 Pre-stained standard (Invitrogen) was used to estimate the molecular weight of the proteins. Membranes were blocked for 1 hr at room temperature (RT) in 5% (w/v) skim milk diluted in 0.05 M Tris-buffered saline/0,05% Tween-20 (TBST) with gentle shaking. Rabbit anti-mGluR2/3 (Upstate #06-676) 1:500 or mouse anti-a-actin (Millipore, Copenhagen, Denmark #MAB1501) 1:4000 was diluted in 5% (w/v) skim milk/TBST and membranes incubated overnight at 4°C with gentle shaking. Blots were washed four times with TBST and incubated with HRPconjugated rabbit antimouse or pig anti-rabbit IgG (DAKO #P0260, P0217), diluted 1:2000 in 5% (w/v) skim milk in TBST, for 1 hr at RT with gentle shaking. After being washed, the membranes were imaged with SuperSignal Extended duration substrate (Thermo Scientific) using a Carestream CCD camera and the optical density of each band was quantified using Image Lab software (Bio-Rad). Protein expression levels were normalized to the intensity of the a-actin band. fig. 1G-L) . No CNPase-positive oligodendroglial cells were detected in either proliferating or differentiated hNS1 cells, which is in agreement with previous reports [20, 22] . MGluR2/3 was present on both b-tubulin IIIpositive and GFAP-positive differentiated cells ( fig. 1G- 
L).
MGluR2/3 activation increases stem cell proliferation. Three days of mGluR2/3 activation by DCG-IV exposure increased the number of stem cells by 60% relative to untreated controls. No significant differences were seen when mGluR2/3 was antagonized with LY341495 during proliferation either alone or in combination with DCG-IV (fig 2A) . The observed increase in cell numbers was due to enhanced proliferation and not reduced cell death, as similar numbers of pycnotic/fragmented nuclei were found in proliferating DCG-IV-treated cultures and controls ( fig. 3) . Differential expression of dimeric mGluR2/3 on proliferating and differentiated cells.
To investigate the mechanism responsible for the lack of effect of DCG-IV treatment during cell differentiation, Western blotting for mGluR2/3 was performed under non-denaturing conditions (dimeric GluR2/3 is the active form of the receptor). Dimeric mGluR2/3 was expected to cause a band around 190 kDa, and the bands observed below this molecular weight were unlikely to represent the functional dimer (may potentially reflect other splice variants and differences in relative charge or post-translational modifications). For this reason, only the bands situated around 190 kDa were quantified. Levels of monomeric mGluR2/3 were similar in proliferating and differentiated stem cells, whereas the level of the dimeric form was significantly reduced to around 25% after cell differentiation ( fig. 5 ). This may explain why mGluR2/3 activation through DCG-IV affected only proliferating and not differentiating cells in our study.
Discussion
Several studies suggest that ligands acting on metabotropic glutamate receptors (mGluRs) play a major role in controlling CNS development and potentially also adult neurogenesis [11, 13, 14, 16, 24] , but also a variety of other molecules and receptors, including the ionotropic glutamate receptors (iGluRs), seem to be involved [25] . The general significant focus on mGluRs may reflect that these receptors modulate a number of intracellular cascades of which many are leading to altered gene expression [26] [27] [28] [29] [30] .
The stem cells used in the present study (hNS1 cells) expressed mGluR2/3 both during proliferation and following differentiation. MGluRs are highly expressed during neural development [7] [8] [9] [10] , but to our best knowledge, this is the first time expression of mGluR2/3 has been shown for human neural stem cells (NSCs). When added during cell propagation, the mGluR2/3 agonist DCG-IV increased the total cell number by 60% without affecting cell viability. As DCG-IV is a relatively selective mGluR2/3 agonist at the concentration (1 lM) applied in our study (acts on other mGluRs and iGluRs at higher concentrations), this clearly suggests that activation of group II mGluRs on these cells stimulates proliferation. This is in line with results from another study showing that pharmacological blockade of group II mGluRs reduces proliferation of human glioma cells [31] . Interestingly, others have reported that DCG-IV reduces astroglial proliferation in cell cultures [32] .
Obviously, the present in vitro study, with pharmacological manipulations of mGluR2/3, cannot be expected to fully mimic the much more complex in vivo situation, where the microenvironment is different and where temporal and spatial changes are expected to occur. However, it is tempting to speculate that similar regulatory mechanisms may play a role during certain stages of brain development or in regions with stem cells and neurogenesis in the adult brain, but in vivo studies are clearly needed to address such issues.
As several studies have shown that activation of group II mGluRs is neuroprotective [33, 34] , we performed a Hoechst staining and did morphological analyses to estimate whether mGluR2/3 activation was affecting cell survival [23] . However, no difference in the relative content of apoptotic or necrotic cells was observed, demonstrating that the increased cell numbers seen after DCG-IV treatment were caused by an increase in cell proliferation. Although the group II antagonist LY341495 could inhibit the DCG-IV induced proliferation, it did not on its own affect the proliferation of the stem cells.
In our studies, we reduce or avoid the use of exogenous glutamate supplements in the cell culture media due to the risk of spontaneous mGluR activation already before agonist/antagonist treatment. One concern is that activation of mGluR2/3 by such glutamate supplements could increase cell proliferation and thus inhibit the effect of an agonist when added on its own. Most likely, we detected no effect of the antagonist alone because the receptors were not activated before DCG-IV was applied.
Combined, our results indicate that mGluR2/3 activation is not strictly required but can positively affect proliferation of human NSCs. A possible explanation could be that mGluR2/3 receptors are known to be coupled to the MAPK pathway [28] , which can be activated by growth factors and mediate a proliferative response [35] . Whether MAPK activation is responsible for the increased proliferation seen in this study requires further investigation.
Group II receptor activation during spontaneous differentiation did not influence the resulting numbers of astrocytes and neurons. The observed different effect of mGluR2/3 activation on proliferating versus differentiated cells correlates well with our finding of significantly more dimeric, active mGluRs on proliferating cells compared to differentiated cells [36] .
The finding that pre-treatment with DCG-IV during propagation lowered the percentage of b-tubulin III-positive neurons detected after differentiation may indicate that the cells were more likely to differentiate into astrocytes after mGluR2/3 stimulation. Another possible explanation could be that a continuously increased number of proliferative cells lowered the relative content of b-tubulin III-positive cells in the cultures. However, for detailed clarification of the involved mechanisms, further investigations are needed.
In conclusion, we have shown that the mGluR2/3 receptors are expressed on proliferating human forebrain-derived NSCs as well as neurons and astrocytes resulting from their differentiation. Furthermore, we have established that mGluR2/3 receptor activation can stimulate stem cell proliferation, but does not affect cell differentiation significantly as the active, dimeric mGluR receptor is mainly expressed by proliferating NSCs. This further emphasizes the importance of glutamate and its receptors in stem cell regulation. Fig. 5 . Expression of the active, dimeric metabotropic glutamate receptor 2/3 (mGluR2/3) on proliferating and differentiating human neural stem cells. After 10 days of differentiation, Western blotting for mGluR2/3 showed a significant decrease in the level of dimeric mGluR2/3 compared to that of proliferating cells. Data are shown as mean AE S.E.M.; protein from two independent differentiations. **p < 0.01; Student's t-test.
